AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02205372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00567203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04238377
Drug: Multimodal Analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
Trial: NCT03119948
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment
Trial: NCT02116790
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take one 250mg Naproxen capsule
Trial: NCT02116790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take two placebos.
Trial: NCT01195948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule with no active ingredients to mimic B27PD
Trial: NCT02616783
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Trial: NCT02616783
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/300 mg tablet administered orally once daily
Trial: NCT02616783
Drug: Third agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG
Trial: NCT00248651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
Trial: NCT03119558
Drug: 18F-Florbetaben (Neuraceq®) PET/MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
Trial: NCT05225545
Drug: Sucrosomial Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Arm
Trial: NCT05225545
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT02566044
Drug: QBW276
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg and 1.5 mg strengths
Trial: NCT00794820
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg/m\^2 by vein over 60 minutes daily for 3 days (days 2-4)
Trial: NCT03748134
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m\^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W
Trial: NCT03748134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
Trial: NCT03106116
Drug: Standard medical therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline- driven standard medical treatment for 7 weeks
Trial: NCT04009603
Drug: Probiotic Agent
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit effects on the host.~Many clinical trials have been done on probiotic which show its use as a single or as an adjuvant drug therapy for various diseases with no or rare side effects. It is now frequently used agent for various diseases.~Apart from this many studies have been published related to effects of probiotics on PCOS, which shows effectiveness of probiotics when used for 8 to 12 weeks with no adverse effects observed by these micro-organisms but none of the study have compare it with standarad drug
Trial: NCT00115310
Drug: NGX-4010
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03662126
Drug: KRT-232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRT-232, administered by mouth
Trial: NCT03662126
Drug: Best Available Therapy (BAT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best available therapy options include:~1. hydroxyurea~2. chemotherapy or~3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed).
Trial: NCT01150630
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/mq/day per os for 14 days every 14 days for 6 months
Trial: NCT02124811
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03690583
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 10 mg for children younger than 1 year old, 20 mg for children older than 1 year old, will be diluted in 1 ml of sterile water and administered orally every day in the morning during hospitalization
Trial: NCT03226457
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
Trial: NCT00477763
Drug: Restasis, Refresh Endura
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening~2. Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening
Trial: NCT03679013
Drug: Oral Gabapentin and Intravenous Acetaminophen (IV APAP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scheduled multimodal pain regimen consisting of oral Gabapentin paired with intravenous Acetaminophen following cardiopulmonary bypass surgery.
Trial: NCT03679013
Drug: Opiate based pain regimen.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care opiate based pain regimen.
Trial: NCT01591733
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to Eight-14 day cycles
Trial: NCT02955953
Drug: LY2963016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01591733
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally, for 10 days
Trial: NCT04165031
Drug: LY3499446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03080740
Drug: Clindamycin palmitate hydrochloride dispersible tablet
RxNorm normalized name: Clindamycin Palmitate Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg, oral after meal, twice daily, a total of 7days
Trial: NCT03794492
Drug: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Orally, up to 1g BID(total 2g daily)
Trial: NCT03794492
Drug: Methylprednisolone/prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Methyprednisolone 500mg / Prednisolone 5mg
Trial: NCT01718483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once-daily, orally, for up to 12 weeks
Trial: NCT00904475
Drug: Lidoderm®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
Trial: NCT01125631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every 8 weeks (4 doses total)
Trial: NCT00328861
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
Trial: NCT02584283
Drug: Glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
Trial: NCT02962310
Drug: Torrent's Rosuvastatin Calcium Tablets 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, crossover
Trial: NCT02962310
Drug: Crestor 40 mg Tablets of AstraZeneca LP, USA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, crossover
Trial: NCT05366595
Drug: oral zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral zinc sulfate at dose 10 to 20 mg daily for 10 days
Trial: NCT02185417
Drug: Chlorthalidone (CTD)
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial activities following study randomization were considered as usual care. Prescriptions of the allocated drug were managed by the primary care providers and patients would receive the prescribed mediations through the VA outpatient pharmacy services.
Trial: NCT00984932
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg of rosuvastatin daily
Trial: NCT04623866
Drug: Huaiqinhuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
Trial: NCT00678418
Drug: VIVITROL® 380 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
Trial: NCT00678418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
Trial: NCT01500798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily
Trial: NCT03555149
Drug: AB928
RxNorm normalized name: Adenosine A2a and A2b receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.
Trial: NCT01133548
Drug: Testosterone Gel 1.62%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 grams administered using an application Site Rotation
Trial: NCT01133548
Drug: Testosterone Gel 1.62%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 grams administered using an a combination of Application sites
Trial: NCT01948271
Drug: Trichuris Suis Ova
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
Trial: NCT03303495
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle
Trial: NCT03303495
Drug: l-LV (dl-LV)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
Trial: NCT02365727
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03826940
Drug: Lovastatin 60 MG
RxNorm normalized name: lovastatin 60 MG
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 MG Lovastatin per day for 3 consecutive days
Trial: NCT03787459
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir plus placebos will be administrated from Days 1-7.
Trial: NCT04021979
Drug: 1.5L PEG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume PEG
Trial: NCT01342289
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.
Trial: NCT03292016
Drug: APO-go
RxNorm normalized name: APO-Go
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous APO-go
Trial: NCT03810183
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet + Standard of Care
Trial: NCT03810183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 6 weeks administered orally as a tablet + Standard of Care
Trial: NCT01443858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
Trial: NCT03487770
Drug: Placebo Oral Solution
RxNorm normalized name: Placebo Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2\~15 mg/day (2\~15 mL/day)
Trial: NCT01630135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, intranasal, 2 weeks
Trial: NCT00306046
Drug: Bisphosphonate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02565316
Drug: Nepeta menthoides Boiss & Bohse freeze dried extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03826940
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 MG Placebo per day for 3 consecutive days
Trial: NCT03563157
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: XELODA® tablets
Trial: NCT01124318
Drug: Lactofiltrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
Trial: NCT01124318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 tablets 3 times a day before meals during 21 days
Trial: NCT04368507
Drug: YYB101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. b (Dose level 0 cohort): YYB101 20mg/kg, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity~2. a Stage 1: YYB101 RP2D, Irinotecan 150 mg/m2 of each dose level, IV infusion on Day 1, Day15, and followed by every 2 weeks until disease progression or unacceptable toxicity
Trial: NCT04576728
Drug: Trimodulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP will be administered via IV infusion on 5 consecutive days.
Trial: NCT03563157
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide Capsules
Trial: NCT03563157
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin Calcium
Trial: NCT03200210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills manufactured to mimic Febuxostat tablets
Trial: NCT01579513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
Trial: NCT02417753
Drug: AZD9150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
Trial: NCT03551847
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention involves not giving an infected patient antibiotics.
Trial: NCT01406561
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
Trial: NCT03502499
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of normal saline as an irrigant for open-irrigated ablation catheters
Trial: NCT00933062
Drug: SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
Trial: NCT00933062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
Trial: NCT00636584
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03472053
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
Trial: NCT02100046
Drug: Zarontin® (ethosuximide) and Stodal®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02551718
Drug: In Vitro Sensitivity-Directed Chemotherapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive personalized chemotherapy with one or more of the following drugs:~Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin
Trial: NCT02662452
Drug: GLPG2222 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single ascending doses, oral suspension
Trial: NCT02662452
Drug: Placebo single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single doses, oral suspension, matching placebo
Trial: NCT02662452
Drug: GLPG2222 multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple ascending doses, daily for 14 days, oral suspension
Trial: NCT02662452
Drug: Placebo multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses, daily for 14 days, oral suspension, matching placebo
Trial: NCT00176865
Drug: Campath 1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6
Trial: NCT00555074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, BID, oral route during 6 weeks
Trial: NCT05002595
Drug: H. pylori eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial agents for H. pylori eradication
Trial: NCT00424281
Drug: Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00994136
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
Trial: NCT04536662
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.